

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/010468

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K45/06 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/052292 A (BHALLA KAPIL N ; UNIV SOUTH FLORIDA (US)) 24 June 2004 (2004-06-24) claims; table 1	1-14
P, X	GUO F ET AL: "Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/ Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells" CANCER RESEARCH 01 APR 2004 UNITED STATES, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2580-2589, XP002313871 ISSN: 0008-5472 the whole document	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

18 January 2005

Date of mailing of the international search report

27/01/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Winger, R

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/010468

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GUO FEI ET AL: "Co-treatment with histone deacetylase inhibitors suberoylanilide hydroxamic acid (SAHA) enhances Apo-2L/TRAIL-induced death inducing signaling complex and apoptosis of human acute lymphoid leukemia cells."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), page 154, XP001205005</p> <p>&amp; 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003</p> <p>ISSN: 0197-016X</p> <p>abstract</p>	1-14
X	<p>ROSATO ROBERTO R ET AL: "Histone deacetylase inhibitors interact in a highly synergistic manner with TRAIL to induce mitochondrial damage and apoptosis in human leukemia cells"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), page 701, XP001156354</p> <p>&amp; 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002</p> <p>ISSN: 0197-016X</p> <p>abstract</p>	13,14
Y		1-14
X	<p>MITSIADES NICHOLAS ET AL: "Molecular sequelae of histone deacetylase inhibition in human malignant B cells."</p> <p>BLOOD. 15 MAY 2003, vol. 101, no. 10, 15 May 2003 (2003-05-15), pages 4055-4062, XP002313873</p> <p>ISSN: 0006-4971</p> <p>page 4058, column 1, paragraph 2; figure 6</p>	13,14
Y		1-14
X	<p>INOUE HIDEKAZU ET AL: "Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis."</p> <p>INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. MAY 2002, vol. 9, no. 5, May 2002 (2002-05), pages 521-525, XP009007225</p> <p>ISSN: 1107-3756</p> <p>abstract; tables I,II</p>	13,14
Y		1-14
	----- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/010468

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 763 223 A (GOODWIN RAYMOND G ET AL) 9 June 1998 (1998-06-09) cited in the application column 17, line 57 - column 18, line 5; examples 8,9	1-14
Y	WO 02/22577 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); BAIR KENNETH WALTER () 21 March 2002 (2002-03-21) cited in the application page 81, paragraph 2; claims 37,38; examples	1-14

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/010468

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 2, 5-7, 11-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/010468

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	2004052292	A	24-06-2004	WO	2004052292	A2	24-06-2004
US	5763223	A	09-06-1998	US	6284236	B1	04-09-2001
				US	2004052788	A1	18-03-2004
				US	6521228	B1	18-02-2003
				AU	5596599	A	13-01-2000
				AU	708239	B2	29-07-1999
				AU	6340796	A	30-01-1997
				CA	2225378	A1	16-01-1997
				EP	0835305	A1	15-04-1998
				JP	11508445	T	27-07-1999
				NO	976045	A	02-03-1998
				NZ	311982	A	30-08-1999
				WO	9701633	A1	16-01-1997
WO	0222577	A	21-03-2002	AU	8212901	A	26-03-2002
				BR	0113669	A	03-06-2003
				CA	2420899	A1	21-03-2002
				CN	1450991	T	22-10-2003
				CZ	20030573	A3	18-06-2003
				WO	0222577	A2	21-03-2002
				EP	1318980	A2	18-06-2003
				HU	0300880	A2	28-08-2003
				JP	2004509105	T	25-03-2004
				MX	PA03001832	A	04-06-2003
				NO	20030867	A	25-02-2003
				NZ	524365	A	26-11-2004
				PL	361408	A1	04-10-2004
				SK	2422003	A3	11-09-2003
				US	2004024067	A1	05-02-2004
				US	2003018062	A1	23-01-2003
				ZA	200301423	A	21-04-2004